High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer

Journal of Pathology

Volumn 231, Issue 4, 2013, Pages 433-440

  Emerson, Ryan O ^a   Sherwood, Anna M ^a   Rieder, Mark J ^a   Guenthoer, Jamie ^b   Williamson, David W ^a   Carlson, Christopher S ^b   Drescher, Charles W ^b,c   Tewari, Muneesh ^b,c   Bielas, Jason H ^b   Robins, Harlan S ^b  

^a ADAPTIVE BIOTECHNOLOGIES   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

high throughput sequencing; ovarian carcinoma; T cells; tumour heterogeneity; tumour infiltrating lymphocytes (TILs)

Indexed keywords

T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADAPTIVE IMMUNITY; ARTICLE; CANCER PROGNOSIS; CELL ASSAY; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLONAL VARIATION; EXPRESSED SEQUENCE TAG; FEMALE; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC DIFFERENCE; GENETIC HETEROGENEITY; GENETIC SIMILARITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE CLONE; LYMPHOCYTIC INFILTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; OVARY CARCINOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; T LYMPHOCYTE; TISSUE SECTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

HIGH-THROUGHPUT SEQUENCING; OVARIAN CARCINOMA; T CELLS; TUMOUR HETEROGENEITY; TUMOUR-INFILTRATING LYMPHOCYTES (TILS);

ADAPTIVE IMMUNITY; CLUSTER ANALYSIS; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; GENE REARRANGEMENT, BETA-CHAIN T-CELL ANTIGEN RECEPTOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; OMENTUM; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SEQUENCE ANALYSIS, DNA;

EID: 84887167328     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4260     Document Type: Article

References (32)

1. Gooden MJ, de Bock GH, Leffers N, et al,. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
2. de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A, et al,. Cancer and immune response: old and new evidence for future challenges. Oncologist 2008; 13: 1246-1254.
3. Mlecnik B, Bindea G, Pages F, et al,. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011; 30: 5-12.
4. Mansh M., Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med 2011; 84: 381-389.
5. Ascierto PA, Capone M, Urba WJ, et al,. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 2013; 11: 54.
6. Hwang WT, Adams SF, Tahirovic E, et al,. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012; 124: 192-198.
7. Oble DA, Loewe R, Yu P, et al,. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009; 9: 3.
8. Yamada N, Oizumi S, Kikuchi E, et al,. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010; 59: 1543-1549.
9. Gerlinger M, Rowan AJ, Horswell S, et al,. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
10. Lee AJ, Endesfelder D, Rowan AJ, et al,. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011; 71: 1858-1870.
11. Maheswaran S, Sequist LV, Nagrath S, et al,. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
12. Gerlinger M, Swanton C,. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010; 103: 1139-1143.
13. Aktipis CA, Nesse RM,. Evolutionary foundations for cancer biology. Evol Appl 2013; 6: 144-159.
14. Davis MM, Bjorkman PJ,. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395-402.
15. Robins HS, Campregher PV, Srivastava SK, et al,. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009; 114: 4099-4107.
16. Yousfi Monod M, Giudicelli V, Chaume D, et al,. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 2004; 20 (Suppl 1): i379-i385.
17. Saitou N, Nei M,. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4: 406-425.
18. Tamura K, Peterson D, Peterson N, et al,. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28: 2731-2739.
19. Huson DH, Scornavacca C,. Dendroscope 3: an interactive tool for rooted phylogenetic trees and networks. Syst Biol 2012; 61: 1061-1067.
20. Fisher R, Pusztai L, Swanton C,. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108: 479-485.
21. Gorre ME, Mohammed M, Ellwood K, et al,. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
22. Inukai M, Toyooka S, Ito S, et al,. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006; 66: 7854-7858.
23. Shah NP, Nicoll JM, Nagar B, et al,. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
24. Clarke B, Tinker AV, Lee CH, et al,. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009; 22: 393-402.
25. Gavalas NG, Karadimou A, Dimopoulos MA, et al,. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol 2010; 2010: 791603.
26. Sato E, Olson SH, Ahn J, et al,. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-18543.
27. Zhang L, Conejo-Garcia JR, Katsaros D, et al,. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2005; 348: 203-213.
28. Sherwood AM, Emerson RO, Scherer D, et al,. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother 2013; 62: 1453-1461.
29. Galon J, Pages F, Marincola FM, et al,. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10: 1.
30. Ascierto PA, Kalos M, Schaer DA, et al,. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013; 19: 1009-1020.
31. Liu C, Peng W, Xu C, et al,. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19: 393-403.
32. Galon J, Angell HK, Bedognetti D, et al,. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39: 11-26.